About arcus biosciences inc. - RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
RCUS At a Glance
Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward, California 94545
| Phone | 1-510-694-6200 | Revenue | 258.00M | |
| Industry | Biotechnology | Net Income | -283,000,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 120.513% | |
| Fiscal Year-end | 12 / 2025 | Employees | 627 | |
| View SEC Filings |
RCUS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.20 |
| Price to Book Ratio | 2.831 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.742 |
| Enterprise Value to Sales | 2.026 |
| Total Debt to Enterprise Value | 0.304 |
RCUS Efficiency
| Revenue/Employee | 411,483.254 |
| Income Per Employee | -451,355.662 |
| Receivables Turnover | 10.32 |
| Total Asset Turnover | 0.23 |
RCUS Liquidity
| Current Ratio | 4.496 |
| Quick Ratio | 4.496 |
| Cash Ratio | 4.327 |
RCUS Profitability
| Gross Margin | 96.124 |
| Operating Margin | -120.155 |
| Pretax Margin | -109.302 |
| Net Margin | -109.69 |
| Return on Assets | -25.212 |
| Return on Equity | -59.768 |
| Return on Total Capital | -43.944 |
| Return on Invested Capital | -47.01 |
RCUS Capital Structure
| Total Debt to Total Equity | 32.784 |
| Total Debt to Total Capital | 24.689 |
| Total Debt to Total Assets | 13.826 |
| Long-Term Debt to Equity | 30.309 |
| Long-Term Debt to Total Capital | 22.826 |